Indication
Treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.
Medicine details
- Medicine name:
- odevixibat (Bylvay)
- SMC ID:
- SMC2843
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Ultra-orphan reassessment
- Publication due date:
- 08 June 2026
- SMC meeting date:
- 05 May 2026
- Patient group submission deadline:
- 02 March 2026